Omega Therapeutics develops DNA-targeting, mRNA-expressing therapies using its proprietary platform to revolutionize treatment across diseases.

Omega Therapeutics (NASDAQ:OMGA) specializes in harnessing the power of genomic programming to develop a new class of DNA-sequence-targeting, mRNA-expressing therapies with the objective of revolutionizing the treatment across multiple disease areas. Their projects primarily focus on leveraging their proprietary Omega Epigenomic Programming™ platform to precisely tune gene expression, without altering the native DNA sequence, facilitating the development of therapies aimed at a broad range of diseases including oncology, regenerative medicine, and autoimmune diseases. Omega aims to pioneer a new era of genomic medicine, with the goal of unlocking the full potential of the human genome to conquer diseases at their genetic roots.
GET YOUR GRAFA EDGE NOW
Sign up free to follow this company
We'll switch on a 30-day Edge trial as a welcome gift